Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 128.52M | 138.05M | 126.71M | 137.14M | 116.66M | 158.73M |
Gross Profit | 20.77M | 25.48M | 16.61M | 10.44M | -8.39M | -24.28M |
EBITDA | -31.89M | -359.34M | -66.89M | -75.70M | -68.12M | -107.98M |
Net Income | -571.11M | -592.21M | -551.83M | -482.92M | -371.74M | -521.82M |
Balance Sheet | ||||||
Total Assets | 2.22B | 2.03B | 2.26B | 2.82B | 3.35B | 3.50B |
Cash, Cash Equivalents and Short-Term Investments | 35.90M | 23.42M | 19.04M | 32.87M | 31.77M | 153.79M |
Total Debt | 3.00B | 3.16B | 2.86B | 2.86B | 2.82B | 2.92B |
Total Liabilities | 3.33B | 3.52B | 3.18B | 3.21B | 3.16B | 3.31B |
Stockholders Equity | -1.11B | -1.49B | -927.36M | -396.33M | 191.27M | 186.42M |
Cash Flow | ||||||
Free Cash Flow | -50.37M | -6.02M | -46.06M | -6.27M | -97.40M | -101.75M |
Operating Cash Flow | -50.27M | -5.85M | -45.89M | -2.64M | -93.91M | -98.36M |
Investing Cash Flow | 979.00K | -4.07M | -3.36M | -9.39M | -10.19M | -54.53M |
Financing Cash Flow | 42.83M | 14.72M | 44.32M | 17.63M | -29.61M | -1.09B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | HK$392.00M | 9.32 | 5.26% | 10.36% | -5.08% | 27.33% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
62 Neutral | HK$425.22M | 7.01 | 2.19% | 58.55% | 5.32% | 9.79% | |
49 Neutral | HK$357.12M | 38.70 | 2.06% | ― | 0.88% | -25.81% | |
48 Neutral | HK$405.47M | 28.14 | -4.27% | ― | 1303.01% | -45.00% | |
44 Neutral | HK$407.65M | ― | -95.44% | ― | 19.34% | 18.13% | |
43 Neutral | $349.49M | ― | ― | ― | 6.10% | -7.32% |
Man Sang International Limited has issued a positive profit alert, indicating an expected turnaround from a loss to a profit for the six months ending September 2025. This improvement is attributed primarily to a one-off gain from the disposal of Gloryear Investments Limited and its subsidiaries, rather than from recurring business operations. The company emphasizes its commitment to exploring further opportunities to strengthen its core businesses and create long-term shareholder value.
Man Sang International Limited has announced its 2025 Annual General Meeting scheduled for September 24, 2025, in Hong Kong. The meeting will address ordinary business matters such as the re-election of directors and the re-appointment of auditors, as well as special business resolutions concerning the issuance and management of company shares. These resolutions, if approved, could impact the company’s capital structure and shareholder value.
Man Sang International Limited has outlined the terms of reference for its Nomination Committee, which is tasked with identifying and recommending candidates for the company’s board of directors. The committee is responsible for reviewing the board’s structure and composition, ensuring alignment with corporate strategy, and promoting shareholder value. The committee will also assess the independence of directors and make recommendations on appointments and succession planning, contributing to the company’s governance and strategic direction.
Man Sang International Limited has announced a significant change in its executive team with the resignation of Mr. Cheung Tai Chi from his roles as Chief Financial Officer, Company Secretary, and Authorised Representative, effective June 30, 2025. Mr. Wong Chun Kit, a Certified Public Accountant with over a decade of experience, will assume these positions, bringing expertise from his previous role at KPMG, which may impact the company’s financial management and strategic direction.
Man Sang International Limited reported its annual financial results for the year ended March 31, 2025, showing a revenue increase to HK$138,047,000 from HK$126,710,000 in the previous year. Despite the revenue growth, the company faced significant financial challenges, including a substantial loss before tax of HK$590,903,000, attributed to high finance costs and impairment losses on assets, leading to a loss per share of HK(92) cents.